Wilder,
Nice try. BDAL's been on the list for a while (just attached the portfolio/watch list now that a buy has been made), but remains among the QGENFs, TECHs, & PEBs of the watch list. Overvalued wallflowers that won't be invited to my trickle party until they "lose some bloom" by showing some technical weakness or make a minor stumble resulting in major punishment.
Most of the MS pure plays seem overvalued to me at the moment, though I'm all ears for arguments to the contrary and associated picks. So watching to scoop MDZ at 19. It's trading there, but volume is so low, that I don't know if my 300 share order would fill yet. MDZ is something of a trickle conglomerate, seems reasonably valued, and is a leader in the MS space, despite not being a pure play therein.
The Trickle Portfolio's buying policy is such that it will be able to own ~ a dozen stocks. We can probably name about that many trickle categories. It would be a worth while exercise to put together a table of trickle categories and then start pigeonholing companies to the best of our collective ability. Thus allowing the Portfolio to be as "paradigmatic" as possible.
So far, we have small ticket lab items (NBSC); DNA sequencers (MDCC); bioinformatics (INCY, PCOP); mass spectrometers (WAT, MDS, BDAL); lab automation (GNSL?,?); reagents (QGENF, etc.) . . . well, that's what my frazzled brain has come up with at the moment. I've probably got a mismatch or two in there, but y'all get the idea.
Help the Trickle Portfolio find its indentity!
Cheers, Tuck |
